Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Cancer Discov. 2018 Feb 15;8(6):696–713. doi: 10.1158/2159-8290.CD-17-1260

Table 2B.

PD-L1 expression in GEA Foundation Medicine cohort, by EGFR amplification status

All GEA EGJ Gastric GEA EGFR WT GEA EGFR AMP

No. cases with PD-L1 IHC 632 377 255 591 41

PD-L1 tumor (%)
 High positive 20 (3) 12 (3) 8 (3) 20 (3) 0
 Low positive 89 (14) 56 (15) 33 (13) 84 (14) 5 (12)
 Negative 523 (83) 309 (82) 214 (84) 487 (82) 36 (88)

PD-L1 TILs (%)
 High positive 1 (0.2) 0 1 (0.4) 1 (0.2) 0
 Low positive 110 (17) 72 (19) 38 (15) 105 (18) 5 (12)
 Negative 521 (82) 305 (81) 216 (85) 485 (82) 36 (88)

PD-LI CPS (%)
 Positive (≥1%) 166 (26) 106 (28) 60 (24) 159 (27) 7 (17)
 Negative 466 (74) 271 (72) 195 (76) 432 (73) 34 (83)